Sequel and Senseonics Launch twiist Automated Insulin Delivery with One-Year CGM
Sequel Med Tech and Senseonics have launched the twiist Automated Insulin Delivery system integrated with the Eversense 365 one-year CGM, now available across the U.S. for type 1 diabetes patients. The combination cuts sensor changes with 365-day monitoring and uses Tidepool-powered algorithms for precise, adaptive insulin dosing.
1. Integration Launch and Availability
Sequel Med Tech and Senseonics have rolled out the twiist Automated Insulin Delivery system fully integrated with the Eversense 365 CGM, making it broadly available across U.S. care settings for people with type 1 diabetes. This marks the first AID solution compatible with a one-year continuous glucose monitor, expanding options for long-term management.
2. Technology and Clinical Benefits
The combination leverages the Eversense 365 implantable sensor’s one-year lifespan to reduce device replacements, providing uninterrupted glucose data with exceptional accuracy in low ranges. twiist’s microdose delivery measurement and Tidepool-based algorithm automate basal insulin adjustments, support activity presets and flexible targets, and detect blockages up to nine times faster than other pumps.
3. Commercial Outlook and Market Potential
National availability of this integrated system could accelerate adoption among type 1 diabetes patients seeking reduced device burden and enhanced control, potentially boosting recurring revenue from annual sensor procedures versus quarterly replacements. Clear differentiation from short-term CGMs and competitive positioning against Abbott’s Libre 3 Plus may drive market share gains and long-term growth.